<DOC>
	<DOCNO>NCT00667641</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel , work different way stop growth tumor cell , either kill cell stop dividing . Bortezomib may stop growth tumor cell block enzymes need cell growth . Giving paclitaxel together bortezomib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose paclitaxel bortezomib treat patient metastatic unresectable malignant solid tumor .</brief_summary>
	<brief_title>Paclitaxel Bortezomib Treating Patients With Metastatic Unresectable Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - To identify maximum tolerate dose paclitaxel combination bortezomib patient metastatic unresectable solid tumor malignancy involve activate Ras/Raf/MAPK pathway . Secondary - To assess toxicity regimen . - To assess tumor response patient . - To determine whether Bim upregulated peripheral blood mononuclear cell obtain patient treated regimen . - To correlate marker Ras/Raf/MAPK pathway activation fresh archive tumor tissue clinical response patient . - To perform pharmacokinetic ( PK ) study determine whether bortezomib alters paclitaxel PK parameter . OUTLINE : Patients receive paclitaxel IV 1 hour bortezomib IV day 1 , 8 , 15 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Blood sample collect baseline periodically course 1 pharmacokinetic biomarker study . Blood sample analyze plasma concentration paclitaxel high performance liquid chromatography Bim protein level phosphorylation status western blotting . Tumor tissue sample , available , analyzed evaluate presence activate Ras/Raf/MAPK pathway . Tumor tissue sample analyze Ras and/or Raf mutation nucleic acid extraction direct sequencing ; Ras and/or Raf overexpression western blotting ; Ras activation assay ; and/or phospho-ERK western blotting IHC .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor involve activate Ras/Raf/MAPK pathway , include follow : Breast cancer Prostate cancer Colon cancer Pancreatic cancer Ovarian cancer Nonsmall cell lung cancer Melanoma Papillary thyroid cancer Metastatic unresectable disease Standard curative palliative measure exist longer effective No newly diagnose , untreated , uncontrolled brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/μL WBC ≥ 3,500/μL Platelet count ≥ 100,000/μL Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST/ALT ≤ 2.5 time ULN ( ≤ 5 time ULN tumor involvement liver ) Creatinine ≤ 2 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No neuropathy ≥ grade 1 pain within past 14 day No active infection No myocardial infarction within past 6 month No NYHA class III IV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No evidence acute ischemia active conduction system abnormality ECG Any ECG abnormality screen must document investigator medically relevant No hypersensitivity bortezomib , boron , mannitol No serious medical psychiatric illness likely interfere study participation PRIOR CONCURRENT THERAPY : Prior paclitaxel bortezomib allow At least 4 week since prior chemotherapy and/or radiotherapy More 14 day since prior investigational drug No concurrent investigational agent No concurrent anticancer agent , include chemotherapy biologic agents No concurrent recombinant interleukin11 ( Neumega® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
</DOC>